John McDonough, executive chair and CEO of Sunbird Bio, discusses the company’s diagnostic test in development for Alzheimer’s disease, how it has the potential to impact treatments and outcomes for millions of patients with the condition, and how its merger with Glympse Bio is expected to push it into new markets.

Christina Smolke, co-founder and CEO of Antheia, about the supply-chain challenges underlying drug shortages, how the company is using synthetic biology to create a reliable supply of active pharmaceutical ingredients, and its growing pipeline of products in development.

Thomas Rademacher, co-founder and CEO of Emergex Vaccines, discusses the company’s platform technologies, the manufacturing advantages they offer, and its pursuit of universal coronavirus and influenza vaccines that work across variants.

Stacy Blain, co-founder and chief scientific officer of Concarlo, discusses the development of drug resistance in cancer, the company’s initial focus on breast cancer, and her own journey from academia to biopharma.

Howard Davis, CEO of Akamis Bio, discusses the challenges immunotherapies have faced in addressing solid tumors, the company’s tumor gene therapy platform, and how it turns tumors against themselves to stimulate an immune response.

David Longo, co-founder and CEO of Ordaōs, discusses the company’s focus on mini-proteins, its generative AI platform, and why its building its own pipeline around rare disease indications and partnering with other drug developers on other indications.

Connie Chang, chief operating officer for ONL Therapeutics, discusses the role Fas-signaling plays in cell death, how this underlies a number of retinal diseases, and the company’s experimental therapy to inhibit Fas signaling to treat these conditions.

James Field, founder and CEO of LabGenius, discusses the company’s use of generative AI to discover new therapeutic antibodies, its initial focus on immunotherapies, why he thinks the data the company is generating to train its AI system is a significant point of differentiation.

Ketan Mehta, founder and CEO of Tris Pharma, discusses its experimental opiod Cebranopadol, how it modulates the addictive potential by targeting two receptors at once, and its potential to address the opioid crisis.

Tzvia Bader, co-founder and CEO of Leal Health, discusses her own experience with cancer, how that led to the creation of Leal Health, and how it is harnessing AI to connect patients to clinical trials based on their exact diagnoses.

Simeon George, CEO and managing partner for SR One, about the firm’s investment approach, how the current landscape is causing venture capitalists and therapeutics developers to think differently, and what advice he’d offer entrepreneurs seeking to raise money today.

Bonum Therapeutics Chief Scientific Officer Diane Hollenbaugh and Bonum Chief Business Officer Neela Patel discuss the therapeutic potential of cytokines, the challenges of using them as therapeutics, and why Bonum’s context-dependent cytokines may enable wider use of these proteins to treat a range of diseases

Pascal Touchon, president and CEO of Atara Biotherapeutics, discusses the role of the Epstein-Barr virus in certain cancers and autoimmune conditions, the company’s platform technology for allogenic CAR T therapies, and why it has implications beyond EBV-driven diseases.

Randy Schatzman, CEO of Bolt Biotherapeutics, discusses the company’s immune-stimulating antibody conjugates, the case for activating both the innate and adaptive immune systems to fight cancer, and the company’s lead experimental therapy for HER2 positive cancers.

Thomas VanCott, chief scientific officer of Combined Therapeutics, discusses the company’s mRNA platform for vaccines, the advantages it provides, and its potential to use the same approach to train the immune system on specific mutations in a tumor.

Chris Pirie, co-founder and chief operating officer of HDT Bio, discusses the problem antibiotic resistance in developing nations, its platform technology for producing safe and stable RNA vaccines, and the potential to use the same platform to produce immunotherapies for cancer.

Jonathan Solomon, CEO of BiomX, discusses the case for phage therapies, the company’s approach to creating a phage cocktail that could effectively target a population of patients, and why it’s focusing on chronic diseases.

Wee Kiat Tan, chief operating officer of CytoMed, discusses the company’s platform technology for off-the-shelf CAR T therapies, the advantages they provide over existing autologous CAR T therapies, and why he believes they will be successful at treating solid tumors.

Max Krummel, founder and managing member of Foundery Innovations, discusses the venture studio’s business model, the resources it brings to bear, and how it works with academic researchers and universities.

Nick Colangelo, president and CEO of Vericel, discusses the sports medicine and burn care markets the company is targeting, how its products are changing outcomes for patients, and the company’s plans for growth.

Ken Bloom, head of pathology for Nucleai, discusses the company’s AI spatial biology platform, how it works, and the potential it has to advance precision medicine.

Bill Enright, CEO of Vaccitech, discusses the company’s platform technologies, how they work, and how they enable the development of more effective immunotherapies.

Jak Knowles, CEO of Affini-T Therapeutics, discusses the company’s TCR-T cell therapies that target the drivers of a cancer, how they are engineered, and why they have the potential to be effective at treating solid tumors that have evaded the power of CAR T therapies.

Nader Sanai, director of the Ivy Brain Tumor Center and chief of neurosurgical oncology at the Barrow Neurological Institute, discusses phase 0 clinical trials, how they work, and how they are allowing the center to take a precision medicine approach to treating patients with brain tumors.

Karen Zaderej, CEO of Axogen, discusses peripheral nerve injuries, the company’s portfolio of products, and how it is changing the way surgeons can repair and regenerate damaged nerves.